The Neurofibromatoses drugs in development market research report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neurofibromatoses. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Neurofibromatoses - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued products.

GlobalData tracks 33 drugs in development for Neurofibromatoses by 30 companies/universities/institutes. The top development phase for Neurofibromatoses is phase ii with 13 drugs in that stage. The Neurofibromatoses pipeline has 31 drugs in development by companies and two by universities/ institutes. Some of the companies in the Neurofibromatoses pipeline products market are: Bristol-Myers Squibb, Healx and Therillume.

The key targets in the Neurofibromatoses pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), and Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1).

The key mechanisms of action in the Neurofibromatoses pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Inhibitor with seven drugs in Phase III. The Neurofibromatoses pipeline products include 12 routes of administration with the top ROA being Oral and seven key molecule types in the Neurofibromatoses pipeline products market including Small Molecule, and Gene Therapy.

Neurofibromatoses overview

Neurofibromatosis (NF) is a term for a group of genetic disorders that cause benign tumors to grow on nerve tissue. There are three types of NF: NF1, NF2, and schwannomatosis. Each type has different signs and symptoms, such as skin spots, freckles, bumps, hearing loss, vision loss, pain, and bone deformities. NF is caused by mutations in certain genes that regulate nerve cell growth and division. NF can be inherited from a parent or occur spontaneously during early development. NF affects the nervous system, including the brain, spinal cord, and peripheral nerves. NF has no cure, but treatments can help manage the symptoms and complications. Surgery, radiation therapy, chemotherapy, and medication are some of the options available. NF is one of the most common genetic diseases in the US, affecting about 1 in 3,000 people.

For a complete picture of Neurofibromatoses’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.